Form 4: Pfizer Executive Vice President Sally Susman Reports Stock Appreciation Rights Earn-Out
SEC Form 4
Executive Vice President of Pfizer, Sally Susman, reports the earn-out of stock appreciation rights and related transactions.
Summary
- Sally Susman, an Executive Vice President at Pfizer Inc., reported transactions related to the earn-out of stock appreciation rights on February 22, 2025.
- The transactions included the acquisition of 63,573 shares of common stock through the earn-out of stock appreciation rights at a price of $30.17.
- Shares were withheld to satisfy tax obligations (2,785 shares at $26.3) and to cover the exercise price (56,715 shares at $26.08) in connection with the earn-out.
- Following these transactions, Susman directly owns 165,684 shares of Pfizer common stock and indirectly owns 866 shares through a Rule 16b-3 plan.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common among publicly traded companies like Pfizer.
Comparison to Industry Standards
- Executive compensation practices, including the use of stock appreciation rights, are common in the pharmaceutical industry.
- Companies like Johnson & Johnson, Merck, and AbbVie also utilize similar equity-based compensation plans for their executives.
- The specific terms and amounts of these plans vary based on company performance, individual contributions, and overall compensation strategy.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects the standard compensation practices for Pfizer executives.
- The earn-out of stock appreciation rights incentivizes the executive to contribute to the company's success, aligning their interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/22/2025 | Date of earliest transaction: Earn-out of stock appreciation rights, withholding of shares for tax obligations and exercise price. |
| 02/21/2025 | Closing price of Pfizer common stock used for tax withholding calculation. |
| 02/24/2025 | Date of Power of Attorney signature. |
| 02/25/2025 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.